• November 13, 2018

Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S - Odessa American: Business

e-Edition Subscribe

Ira Duarte Promoted to Chief Financial Officer of Veloxis Pharmaceuticals A/S

Print
Font Size:
Default font size
Larger font size

Posted: Wednesday, October 31, 2018 2:16 pm

COPENHAGEN, Denmark, Oct. 31, 2018 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (NASDAQ: VELO) today announces the promotion of Ira Duarte to Chief Financial Officer. Ms. Duarte has served as the vice-president of finance for Veloxis Pharmaceuticals, Inc. since February 2016 where she has been responsible for all finance and accounting related functions including financial reporting, treasury, budgeting and tax.

Craig Collard, CEO of Veloxis Pharmaceuticals A/S, said "I am really excited to promote Ira Duarte to CFO of Veloxis. Ira has been an incredibly valuable member of the team since joining Veloxis. I look forward to her continued success in this new role."

Prior to joining Veloxis, Ms. Duarte served as Senior Director, Corporate Finance for Chiesi USA, Inc. Prior to that, Ms. Duarte was the Director of Accounting and Financial Planning at Cornerstone Therapeutics, Inc., where she was a core member of the team guiding the sale of Cornerstone Therapeutics, Inc. to Chiesi Farmaceutici S.p.A. Before transitioning to a corporate role, Ms. Duarte held various roles from Staff to Senior Manager at Ernst & Young, managing financial statement audits, SEC filings and IPOs for clients.

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

View original content to download multimedia: http://www.prnewswire.com/news-releases/ira-duarte-promoted-to-chief-financial-officer-of-veloxis-pharmaceuticals-as-300741555.html

SOURCE Veloxis Pharmaceuticals

© 2018 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Sunny
36°
Humidity: 50%
Winds: N at 13mph
Feels Like: 28°

Your Extended Forecast

Tomorrow

weather
High 46°/Low 28°
Sunny. Highs in the mid 40s and lows in the upper 20s.

wednesday

weather
High 57°/Low 35°
Sunny. Highs in the upper 50s and lows in the mid 30s.

thursday

weather
High 63°/Low 35°
Mainly sunny. Highs in the low 60s and lows in the mid 30s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7670 to sign up today.